معرفی
Dr Panos Sergouniotis is a Wellcome Clinician Scientist and Clinical Senior Lecturer at the University of Manchester, serving as an Honorary Consultant in Ophthalmology and Genetics at the Manchester Royal Eye Hospital and the Manchester Centre for Genomic Medicine, UK. His academic journey includes medical training at the University of Athens, ophthalmology specialization in London, Cambridge and the North West Deanery, and PhD studies at University College London under Andrew Webster and Tony Moore.
- Medical Degree: 2007 (University of Athens)
- PhD: 2012 (University College London)
- FEBO: 2016
- FRCOphth: 2018
- CCT Ophthalmology: 2021
Sergouniotis leads research focused on the fovea, the central retinal area critical for visual acuity. His multidisciplinary approach combines genetic association studies, retinal imaging, and stem cell biology to understand foveal development and its role in retinal disorders like age-related macular degeneration and albinism. His work aims to develop frameworks for preserving and restoring high-resolution vision.
His recent publications demonstrate a strong trend toward integrating genomics, advanced imaging, and machine learning in ophthalmic research. The articles span topics from macular dystrophy genetics to deep learning applications in retinal imaging, reflecting his commitment to translational research at the intersection of multiple disciplines.
- Moorfields Research Medal
- EURETINA Ophthalmologica award
- 2nd place, European Board of Ophthalmology Diploma Examination
- Academy of Medical Sciences Young Investigator Competition Runner-up Prize
- Andrew Tullo Prize
- Daniel Turnberg Cup
Sergouniotis has supervised over 15 pre- and post-doctoral researchers and more than 5 NIHR academic clinical trainees, resulting in 2 completed PhDs and 12 early-career postgraduate degrees. He holds a Wellcome Trust Clinical Research Career Development Fellowship awarded in 2021, which supports his multidisciplinary research group. His work also contributes to the UN Sustainable Development Goals through genomic medicine applications.
His laboratory operates at the interface of genomics, stem cell biology, and advanced ophthalmic imaging, with collaborations spanning multiple institutions including the UK Biobank Eye and Vision Consortium. Current projects include the Oxford Nanopore PromethION initiative, which runs from 2023-2026.
